Anne Wojcicki to purchase again 23andMe and its information for $305 million

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained management over the embattled genetic testing firm after her new nonprofit, TTAM Analysis Institute, outbid Regeneron Prescription drugs, the corporate introduced Friday.

TTAM will purchase considerably all of 23andMe’s belongings for $305 million, together with its Private Genome Service and Analysis Providers enterprise strains in addition to telehealth subsidiary Lemonaid Well being. It’s a giant win for Wojcicki, who stepped down from her function as CEO when 23andMe filed for Chapter 11 chapter safety in March.

Final month, Regeneron introduced it might buy most of 23andMe’s belongings for $256 million after it got here out on prime throughout a chapter public sale. However Wojcicki submitted a separate $305 million bid by means of TTAM and pushed to reopen the public sale. TTAM is an acronym for the primary letters of 23andMe, based on The Wall Avenue Journal.

“I’m thrilled that TTAM Analysis Institute will have the ability to proceed the mission of 23andMe to assist folks entry, perceive and profit from the human genome,” Wojcicki mentioned in a press release.

23andMe gained reputation due to its at-home DNA testing kits that gave prospects perception into their household histories and genetic profiles. The five-time CNBC Disruptor 50 firm went public in 2021 through a merger with a particular goal acquisition firm. At its peak, 23andMe was valued at round $6 billion.

The corporate struggled to generate recurring income and arise viable analysis and therapeutics companies after going public, and it has been tormented by privateness issues since hackers accessed the data of practically seven million prospects in 2023.

TTAM’s acquisition continues to be topic to approval by the U.S. Chapter Courtroom for the Japanese District of Missouri.